CPC A61K 31/554 (2013.01) [A61K 9/0053 (2013.01); A61K 9/14 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01); A61K 47/24 (2013.01); A61K 47/26 (2013.01); A61K 47/34 (2013.01); A61K 47/36 (2013.01); A61K 47/38 (2013.01); A61P 25/18 (2018.01)] | 25 Claims |
1. A method for treating a mental disorder in a human subject, the method comprising orally administering to the human subject suffering from the mental disorder an effective amount of an oral liquid suspension comprising:
(a) quetiapine fumarate;
(b) methylparaben, present in 1±0.2 mg/mL;
(c) sodium benzoate, present in 0.3±0.06 mg/mL;
(d) saccharin sodium dihydrate, present in 0.8±0.04 mg/mL;
(e) sodium phosphate dibasic, present in 0.3±0.06 mg/mL;
(f) sorbitol, present in 21±6 mg/mL;
(g) propylene glycol, present in 22.5±5 mg/mL:
(h) glycerin, present in 50±10 mg/mL;
(i) silicified microcrystalline cellulose, present in 12.6±3 mg/mL;
(j) carboxymethylcellulose sodium, present in 1.8±1.4 mg/mL;
(k) xanthan gum, present in 1.8±0.4 mg/mL;
(l) cherry flavor, present in 2.00±0.04 mg/mL;
(m) FD&C Red No. 40, present in 0.02±0.004 mg/mL;
(n) FD&C Yellow No. 6, present in 0.002±0.0004 mg/mL;
(o) polyethylene glycol 400, present in 50±10 mg/mL;
(p) sucralose, present in 5±1 mg/mL; and
(q) purified water, present in 787.046±150 mg/mL.
|